Gyre Therapeutics
GYRE
48 hedge funds and large institutions have $23.1M invested in Gyre Therapeutics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 10 closing their positions.
0% more funds holding
Funds holding: 48 → 48 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.42% less ownership
Funds ownership: 3.64% → 3.21% (-0.42%)
8% less capital invested
Capital invested by funds: $25.1M → $23.1M (-$1.97M)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$271K |
| 2 |
Goldman Sachs
New York
|
+$137K |
| 3 |
Lazard Asset Management
New York
|
+$113K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$109K |
| 5 |
Jane Street
New York
|
+$98.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.39M |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
-$489K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$264K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$206K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$205K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
51
Aster Capital Management
Dubai,
United Arab Emirates
| – | -$10.6K | -1,447 | Closed |
|
52
Raymond James Financial
St Petersburg,
Florida
| – | -$4.78K | -650 | Closed |
|
|
GI
53
GAMMA Investing
Foster City,
California
| – | -$911 | -124 | Closed |
|
54
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$607 | -80 | -65% |
|
|
RA
55
Rise Advisors
Rochester,
New York
| – | -$397 | -54 | Closed |
|
|
EP
56
Essential Partners
Rancho Santa Fe,
California
| – | -$15 | -2 | Closed |
|
|
IA
57
IFP Advisors
Tampa,
Florida
| – | -$7 | -1 | Closed |
|
GYRE Hedge Fund Activity: Q3 2025 in Review
48 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2025, worth a combined $23.1M — down 7.9% from $25.1M a quarter earlier.
Fund positioning in GYRE was balanced in Q3 2025: 10 funds opened new positions, 10 closed out, 13 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $271K. The largest seller was BlackRock, cutting an estimated $1.39M.
- 48 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $23.1M of Gyre Therapeutics stock for Q3 2025, down 7.9% quarter-over-quarter.
- 10 funds opened new Gyre Therapeutics positions in Q3 2025 and 10 closed out, a net change of 0 holders.
- The largest Gyre Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $271K added.
- The largest Gyre Therapeutics seller in Q3 2025 was BlackRock, an estimated $1.39M sold.
Based on aggregated 13F filings for Q3 2025.